GHRP-6 vs Ipamorelin
Both bind the same ghrelin receptor and both trace back to the same first wave of synthetic growth hormone secretagogue research — but they sit at opposite ends of the selectivity spectrum that later defined the entire compound class.
At a Glance
| GHRP-6 | Ipamorelin | |
|---|---|---|
| Category | GHRH & Growth Hormone Peptides | GHRH & Growth Hormone Peptides |
| Molecular class | Synthetic hexapeptide (6 amino acids) | Synthetic pentapeptide (5 amino acids) |
| Discovery timeline | Developed by Cyril Bowers and colleagues at Tulane University, 1980s | Developed at Novo Nordisk, first published 1998 (Raun et al.) |
| Primary mechanism studied | Ghrelin receptor (GHSR1a) agonism — broad, non-selective activation | Ghrelin receptor (GHSR1a) agonism — engineered for selective activation |
| Off-target hormonal activity | Well-documented, reproducible spikes in cortisol, ACTH, and prolactin | Minimal cross-reactivity with cortisol and prolactin pathways |
| Appetite effect | Significant, reliably reproducible increase (orexigenic) | Comparatively minimal appetite effect reported |
| Human clinical trial data | None located — data limited to early receptor-pharmacology studies | None located — data limited to rat and pig pharmacology studies |
| Sold as a blend | Sold standalone only | Yes — see CJC-1295 + Ipamorelin Blend |
How They Differ
GHRP-6 was one of the original synthetic ghrelin-receptor agonists, developed at Tulane University years before ghrelin itself had even been identified as the receptor's natural hormone — its pharmacology is part of how researchers characterized GHSR1a in the first place. That early, unrefined binding conformation activates a wide range of the receptor's downstream signaling, which is why GHRP-6 research reliably reports cortisol, ACTH, and prolactin spikes alongside a pronounced increase in appetite. See its full discovery history.
Ipamorelin arrived roughly two decades later as a direct response to that selectivity problem. Novo Nordisk researchers engineered its binding conformation specifically to trigger pulsatile GH release through GHSR1a without significantly activating the cortisol, ACTH, and prolactin pathways that first-generation secretagogues like GHRP-6 reliably produce. See its full discovery history, or how it compares to Tesamorelin and CJC-1295.
Why They're Often Studied Together
GHRP-6 and Ipamorelin are frequently placed side by side precisely because they bracket the evolution of ghrelin-receptor secretagogue research: GHRP-6 represents the original, broadly-active first generation, while Ipamorelin represents the selectivity-engineered second generation built to solve GHRP-6's off-target activation. Researchers studying receptor selectivity within GHSR1a agonism often reference both to illustrate how much binding-conformation refinement can change a compound's downstream hormonal profile.
GHRP-6 vs Ipamorelin questions
Are GHRP-6 and Ipamorelin interchangeable in research?
No. Both bind the same ghrelin receptor (GHSR1a), but GHRP-6's broader binding conformation reliably triggers off-target cortisol, ACTH, and prolactin activation alongside a strong appetite increase — exactly the cross-reactivity problem Ipamorelin was later engineered to avoid.
Why does GHRP-6 increase appetite more than Ipamorelin?
Both act on GHSR1a in the hypothalamus, but GHRP-6's less selective binding conformation activates the receptor's appetite-stimulating (orexigenic) signaling more strongly than Ipamorelin's selective conformation does, making the appetite effect substantially more pronounced with GHRP-6.
Does this comparison mean either compound is approved for a particular use?
No. This page compares GHRP-6 and Ipamorelin for educational and research context only. Both are sold strictly for laboratory research use and are not evaluated or approved for human or animal use.
Looking for specs and pricing?
View purity, available sizes, and pricing for both.